Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Omega Therapeutics, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
09/26/2023 8-K Quarterly results
08/03/2023 8-K Quarterly results
Docs: "Opinion of Latham & Watkins LLP",
"Open Market Sale Agreement, between Omega Therapeutics, Inc. and Jefferies LLC",
"Omega Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress"
08/03/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/03/2023 10-Q Quarterly Report for the period ended June 30, 2023
07/13/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "WHEREAS, ARE-MA REGION NO. 94, LLC, a Delaware limited liability company entered into that certain Lease dated November 4, 2021, whereby Prime Landlord leased to Licensor, as tenant, approximately 89,246 rentable square feet consisting of approximately 78,380 rentable square feet for the Shared Space Arrangement in the building located at 140 First Street, Cambridge, Massachusetts 02141 . WHEREAS, the parties acknowledge that Licensee meets the definition of a “Flagship Pioneering Entity” as set forth in Section 22 of the Prime Lease. NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Licensor and Licensee hereby agree to the following: 1. License: Licensor hereby grants Licensee, and Licensee hereby accepts from L...",
"WHEREAS, ARE-MA REGION NO. 94, LLC, a Delaware limited liability company entered into that certain Lease dated November 4, 2021, whereby Prime Landlord leased to Licensor, as tenant, approximately 89,246 rentable square feet consisting of approximately 78,380 rentable square feet for the Shared Space Arrangement in the building located at 140 First Street, Cambridge, Massachusetts 02141 . WHEREAS, the parties acknowledge that Licensee meets the definition of a “Flagship Pioneering Entity” as set forth in Section 22 of the Prime Lease. NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Licensor and Licensee hereby agree to the following: 1. License: Licensor hereby grants Licensee, and Licensee hereby accepts from L...",
"WHEREAS, ARE-MA REGION NO. 94, LLC, a Delaware limited liability company entered into that certain Lease dated November 4, 2021, whereby Prime Landlord leased to Licensor, as tenant, approximately 89,246 rentable square feet consisting of approximately 78,380 rentable square feet for the Shared Space Arrangement in the building located at 140 First Street, Cambridge, Massachusetts 02141 . WHEREAS, the parties acknowledge that Licensee meets the definition of a “Flagship Pioneering Entity” as set forth in Section 22 of the Prime Lease. NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Licensor and Licensee hereby agree to the following: 1. License: Licensor hereby grants Licensee, and Licensee hereby accepts from L..."
07/12/2023 4 SCHADE CHRISTIAN S (Director) has filed a Form 4 on Omega Therapeutics, Inc.
Txns: Granted 36,713 options to buy @ $4.69, valued at $172.2k
07/12/2023 3 SCHADE CHRISTIAN S (Director) has filed a Form 3 on Omega Therapeutics, Inc.
07/12/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/12/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
06/09/2023 4 Boehm Rainer J. (Director) has filed a Form 4 on Omega Therapeutics, Inc.
Txns: Granted 18,118 options to buy @ $8.39, valued at $152k
06/09/2023 4 BESHAR LUKE M (Director) has filed a Form 4 on Omega Therapeutics, Inc.
Txns: Granted 18,118 options to buy @ $8.39, valued at $152k
06/09/2023 4 AFEYAN NOUBAR (10% Owner) has filed a Form 4 on Omega Therapeutics, Inc.
Txns: Granted 18,118 options to buy @ $8.39, valued at $152k
06/09/2023 4 MENDLEIN JOHN (Director) has filed a Form 4 on Omega Therapeutics, Inc.
Txns: Granted 18,118 options to buy @ $8.39, valued at $152k
06/09/2023 4 Young Richard A (Director) has filed a Form 4 on Omega Therapeutics, Inc.
Txns: Granted 18,118 options to buy @ $8.39, valued at $152k
06/09/2023 4 Levy Elliott M. (Director) has filed a Form 4 on Omega Therapeutics, Inc.
Txns: Granted 18,118 options to buy @ $8.39, valued at $152k
06/09/2023 4 Szela Mary T (Director) has filed a Form 4 on Omega Therapeutics, Inc.
Txns: Granted 18,118 options to buy @ $8.39, valued at $152k
05/04/2023 8-K Quarterly results
05/04/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/25/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/25/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/24/2023 10-K/A Annual Report for the period ended December 31, 2022 [amend]
03/20/2023 4 Young Richard A (Director) has filed a Form 4 on Omega Therapeutics, Inc.
Txns: Sold 10,000 shares @ $8, valued at $80k
03/10/2023 SC 13G/A FMR LLC reports a 10.1% stake in OMEGA THERAPEUTICS INC
03/02/2023 4 Moore Yan (Chief Medical Officer) has filed a Form 4 on Omega Therapeutics, Inc.
Txns: Granted 55,000 options to buy @ $6.46, valued at $355.3k
03/02/2023 4 McManus Kevin (Chief Human Resources Officer) has filed a Form 4 on Omega Therapeutics, Inc.
Txns: Granted 55,000 options to buy @ $6.46, valued at $355.3k
03/02/2023 4 Karande Mahesh (President and CEO) has filed a Form 4 on Omega Therapeutics, Inc.
Txns: Granted 170,000 options to buy @ $6.46, valued at $1.1M
03/02/2023 4 Zeng Ling (See Remarks) has filed a Form 4 on Omega Therapeutics, Inc.
Txns: Granted 55,000 options to buy @ $6.46, valued at $355.3k
03/02/2023 4 Reed Joshua (CFO) has filed a Form 4 on Omega Therapeutics, Inc.
Txns: Granted 55,000 options to buy @ $6.46, valued at $355.3k
03/02/2023 4 McCauley Thomas (Chief Scientific Officer) has filed a Form 4 on Omega Therapeutics, Inc.
Txns: Granted 55,000 options to buy @ $6.46, valued at $355.3k
03/01/2023 8-K Quarterly results
03/01/2023 10-K Annual Report for the period ended December 31, 2022
02/27/2023 4 Flagship Pioneering Inc. (10% Owner) has filed a Form 4 on Omega Therapeutics, Inc.
Txns: Bought 1,993,986 shares @ $5.78, valued at $11.5M
Bought 1,329,324 shares @ $5.78, valued at $7.7M
02/27/2023 3 Flagship Pioneering Fund VII General Partner LLC (10% Owner) has filed a Form 3 on Omega Therapeutics, Inc.
02/27/2023 SC 13D/A Flagship Ventures Fund V, L.P. reports a 53.2% stake in OMEGA THERAPEUTICS, INC.
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy